Alaunos Therapeutics, Inc.
NCM: TCRTLive Quote
📈 ZcoreAI Score
Our AI model analyzes Alaunos Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get TCRT Z-Score →About Alaunos Therapeutics, Inc.
Healthcare
Biotechnology
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.
📊 Fundamental Analysis
Alaunos Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -25.0% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -198.1%, which indicates that capital utilization is currently under pressure.
At a current price of $2.89, TCRT currently sits at the 27th percentile of its 52-week range (Range: $1.67 - $6.20).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$6.45M
Trailing P/E
--
Forward P/E
-4.82
Beta (5Y)
-1.13
52W High
$6.20
52W Low
$1.67
Avg Volume
16K
Day High
Day Low